Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20
- Stem cells
- cell therapy
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 279305
Licensor grants a non-exclusive, non-transferable license, without the right to grant or authorize sublicenses except as expressly set forth, under the Licensed Patents to make, have made, use, develop, sell, offer to sell, and distribute the Licensed Differentiated Cell Products and Licensed Services in the Field and in the Territory.
Licensed Pluripotent Cell Products means any induced pluripotent stem cell or induced pluripotent stem cell line produced by methods covered by the Licensed Patents.
Licensed Products means both Licensed Differentiated Cell Products and Licensed Pluripotent Cell Products including Cardiomyocytes, Hematopoeitic cells, Neural cells, Hepatocytes, Endothelial cells, Bone cells, Cartilage, Pancreatic cells, Fat cells and Lung cells.
The iPSC technology was pioneered Japan, who showed in 2006 that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells.
Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells.
Pluripotent stem cells hold promise in the field of regenerative medicine. Because they can propagate indefinitely, as well as give rise to every other cell type in the body (such as neurons, heart, pancreatic, and liver cells), they represent a single source of cells that could be used to replace those lost to damage or disease.
IPSCIO Record ID: 7349
Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);
Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensorâ€™s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).
US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells
IPSCIO Record ID: 7550
IPSCIO Record ID: 274909
— a non-exclusive, irrevocable license under Licensorâ€™s Alliance IP Rights, Licensorâ€™s interest in Joint Alliance IP Rights and Licensor Know-How to develop, make, use, sell, have sold, and import products throughout the relevant territories in the Limited Field and,
— a non-exclusive, irrevocable license under Licensorâ€™s Alliance IP Rights and Licensorâ€™s interest in Joint Alliance IP Rights to develop, have developed, make, have made, use, sell, have sold, and import products throughout the relevant territories in the Limited Field.
Licensor grants an option to negotiate in good faith and on commercially reasonable terms
— an exclusive, payable license, with the right to sublicense for the Limited Field under Licensor Alliance IP Rights, and Licensorâ€™s interest in Joint Alliance IP Rights, and;
— a sub-license for the Cellular Assay Products Field in the Territory.
The Licensor Field shall mean therapies that comprise, or are derived from, or developed or manufactured using, human embryonic stem cells.
The Limited Field shall mean products or services that contain cells that comprise, or are derived from, or manufactured using, human embryonic stem cells (and not human induced pluripotent stem cells) in markets outside of the Licensor Field and the Cellular Assay Products Field.
Cellular assay products derived from human embryonic stem cells (hESCs) is for use in drug discovery, development and toxicity screening.
IPSCIO Record ID: 168
Company granted an exclusive license to use its â€œACTCellerateâ€ embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
The licensed rights include pending patent applications, knowledge and the existing bank of cell lines. The licence is exclusive and worldwide for all commercial purposes, including the development of research products, and therapeutic and diagnostic products for human and veterinary use. Licensor has an option to reacquire rights to use the technology for the development of certain types of SCs for human therapeutic use in fields re-lated to its core business.
The technology allows the rapid isolation of novel, highly-purified embryonic progenitor cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of ESCs. These unique cell lines may have potential applications in research, drug discovery and human regenerative SC therapy.
103080-069-WO1 (PCT/US06/13519, filed on 4-11-06) Novel uses of cells with Prenatal Patterns of prenatal gene expression, published as WO2007/058671
103080-071-P61 (USSN 60/791,400, filed on Apr. 11, 2006) Methods to accelerate the isolation of novel cell strains from pluripotent ST
103080-071-P66 (USSN 60/850,294, filed on Oct. 6, 2006), Methods to accelerate the isolation ov novel cell strains from pluripotent stem cells
103080-071-P01 (USSN 11/604,047, filed on Nov. 21, 2006), Methods to accelerate the isolation of novel cell strains from pluripotent STE…
PCT is 103080-071-WO2 (PCT/US2006/45352, filed on Nov. 21, 2006), published as WO 2007/062198.
IPSCIO Record ID: 26667
IPSCIO Record ID: 26263
5,453,366 Method of Cloning Bovine Embryos
6,011,197 Method of Cloning Bovines Using Reprogrammed Non-mbryonic Bovine Cells
6,258,998 Method of Cloning Porcine Animals
5,843,754 Parthenogenic Bovine Oocyte Activation
5,496,720 Parthenogenic Oocyte Activation
09/573,044 Use of embryonic stem cells as nuclear donors during nuclear transfer and use of said techniques to produce chimeric and transgenic animals.
6,194,202 Parthenogenic Oocyte Activation
6,077,710 Parthenogenic Oocyte Activation
6,107,543 Culture of Totipotent Embryonic Inner Cells Mass Cells and Production of Bovine
IPSCIO Record ID: 28403
09/736,268 Transfer to De-Differentiate Recipient Cells
IPSCIO Record ID: 28404
By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field for the following purposes to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays. b) A royalty bearing, twelve (12) month exclusive license in the Territory in the Field to expand in culture, prepare for sale, sell, offer for sale, import and export Act Animal Cell Lines. The twelve-month term of exclusivity granted to Licensee shall begin upon the date of the first sale of the Act Animal Cell Lines. Licensor and Licensee agree that after the twelve-month period of exclusivity has passed, Licensor and Licensee shall negotiate in good faith to establish reasonable minimum sales goals over reasonable evaluation periods in order to maintain Licenseeâ€™s exclusive rights hereunder. If Licensor fails to meet the minimum sales goals then Licenseeâ€™s exclusive rights shall revert to nonexclusive rights.
08/935,052 US 1997-09-22 CICM Cells and Non-Human Mammalian Embryos
6,235,970 2001-05-22 Prepared by Nuclear Transfer of a Proliferating Differentiated Cell or its Nucleus
09/828,876 US 2001-04-10 Cloning Using Donor Nuclei from Differentiated Fetal and Adult Cells UMASS
10/374,512 US 2003-02-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
60/161,987 US 1999-10-28 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
2,387,506 CA 2000-10-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
Declared patent interferences
a) Patent Interference No. 104,746, involving U.S. Patent No. 5,945,577 and U.S. Patent Application No. 09/650,194.
b) Patent Interference No. 105,192, involving U.S. Patent No. 6,235,970 and U.S. Patent Application No. 09/989,126.
Potential patent interferences, verbally threatened to be filed against the following patents
IPSCIO Record ID: 382728
Licensor has the unique strength of combining stem cell research focused on different organs and developmental stages with leading expertise in cellular plasticity, epigenetics and disease models. This unique combination has led to breakthrough discoveries at the crossroads between disease models and repair, cellular plasticity and disease as well as reprogramming.
IPSCIO Record ID: 340079
The transwell migration assay is a commonly used test to study the migratory response of endothelial cells to angiogenic inducers or inhibitors. This assay is also known as the Boyden or modified Boyden chamber assay.
IPSCIO Record ID: 383612
Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.
Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.
Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.
Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.
COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.
Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.
Crohns Indication shall mean the use of Prochymal to treat Crohns disease.
Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.
GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.
Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.
Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.
IPSCIO Record ID: 263
Patent rights shall mean the U.S. Patent Application Number 11/438,790, filed on May 22, 2006 or the equivalent of such application as well as issued patent applications including U.S. Patent Application Number 11/410, 412, 10/984, 645, and 11/132, 687.
IPSCIO Record ID: 6977
Licensor hereby grants Licensee and its Affiliates a world-wide, nonexclusive license under the Licensed Patents and the Licensed Materials to develop, use, provide, and sell Services in the Licensed Field.
Licensor hereby grants Licensee and its Affiliates a world-wide, nonexclusive license under the Licensed Patents and the Licensed Materials to make, develop, use, sell, offer for sale, and import Research Products in the Licensed Field. The grants of this Section 2A shall only apply to those Affiliates for which Licensee has provided written notice to Licensor. Any such identified Affiliates benefiting from such grants shall be bound by all obligations under this Agreement.
Limited Sublicenses – Licensor hereby grants Licensee the right to grant written limited sublicenses under the Licensed Patents to transfer, as applicable, Licensed Materials and/or Derivative Materials to Collaborators, Development Partners and Contract Service Providers, in accordance with the terms of this agreement.
Title – Countries – Issued Patents (U.S.)
Primate Embryonic Stem Cells – US; EP; CA; WO – 7,029,913 5,843,780 6,200,806.
Serum-Free Cultivation of Primate ES Cells – US; AU; BR; CA; CN; EP; HK; IL; IN; IS; JP; KR; MX; NO; NZ; SG – 7,217,569 7,005,252.
Master Human Stem Cell Lines for Gene Expression and Knockdown – US.
Methods Of Making Differentiated Cells From Primate Embryonic Stem Cells – US.
Differentiation of Stem Cells to Endoderm and Pancreatic Lineage – US.
Hematopoietic Differentiation of hESCs – AU; BR; CA; CN; EP; IL; IN; IS; JP; KR; LU; MX; NO; NZ; SE; SG; US; WO – 6,280,718 6,613,568.
Method of In Vitro Differentiation of Transplantable Neural Precursor Cells From Primate ES Cells – US – 6,887,706.
Endothelial Cells Derived from Primate ES Cells – AU; CA; CN; EP; HK; IL; IN; IS; JP; KR; LU; MX; NZ; SE; SG; US – 7,176,023.
Method of Making Embryoid Bodies from Primate ES Cells – US; AU; BR; CA; CN; EP; HK; IL; IN; IS; JP; KR; MX; NO; NZ; SG – 7,220,584 6,602,711.
Method of Forming Mesenchymal Stem Cells from ES Cells – AU; CA; EP; GB; IL; JP; KR; SG; US.
Directed Differentiation of hESCs into Mesenchymal/Stromal Cells – US.
In Vitro Differentiation of Hematopoietic Cells from Non-Human Primate and Human ES Cells – US; WO.
Generation of Clonal Mesenchymal Cells from hESCs in Serum-Free Conditions – US.
Cryopreservation of Pluripotent Stem Cells – US.
Defined Surfaces Of Self-Assembled Monolayers And Stem Cells – US.
Method of Reducing Cell Differentiation – US.
Improved Culture Of Stem Cells – US; WO.
Physiological Culture Conditions for ES Cells – US.
Feeder-Independent Extended Culture of ES Cells – AU; CA; CN; EP; GB; IL; IN; IS; JP; KR; NZ; SE; SG; US.
Cultivation of Primate ES Cells – AU; CA; CN; EP; GB; IL; JP; KR; SG; US.
Directed Genetic Modifications of Human Stem Cells – AU; CA; EP; GB; IL; KR; SG; US.
Method for Generating Primate Trophoblasts – AU; CA; CN; EP; HK; IL; IN; IS; JP; KR; MX; NZ; SG; US – 7,148,062.
Method of In Vitro Differentiation of Neural Stem Cells, Motor Neurons, and Dopamine Neurons from Primate ES Cells – US.
Method of Forming Dendritic Cells from ES Cells – AU; EP; GB; IL; JP; KR; SE; SG; US.
Differentiation of Pluripotent ES Cells – US.
Method of Generating Myelinating Oligodendrocytes from ES Cells – US.
A Method for Generating Keratinocytes and Keratinocyte Precursors from hESCs – US.
Licensed Materials means primate (including human) embryonic stem cells covered by the valid claims in the Licensed Patents and which meet the following conditions
(i) For embryonic stem cells created prior to April 26, 2005, the embryonic stem cell must be either (1) listed on the NIH Human Embryonic Stem Cell Registry at http//escr.nih.gov; or (2) derived from excess embryos created for the purpose' of in vitro fertilization with appropriate consent of the donor couple and not for the purpose of creating embryonic stem cells; or (3) derived from embryos created specifically for research purposes either by in vitro fertilization or by somatic cell nuclear transfer, for which the following additional conditions apply (a) the embryo may not have been maintained in vitro for more than 14 days; (b) the gamete donor(s) and somaticcell donor (if any) made the donation without payment beyond reimbursement for reasonable expenses associated with donation; (c) in the case of egg donation, the donor was fully informed of the risks to herself; (d) the gamete donor(s) and somatic cell donor (if any) were fully informed of the purposes to which their donated materials would be put; (e) the research could not be done equally weU using surplus IVF embryos originally created for reproductive purposes; (f) the research protocol, including gamete collection, somatic cell collection, embryo management and stem cell derivation is approved by an appropriate Institutional Review Board; and (g) protections are in place to prevent misappropriation of embryos created specifically for research.
(ii) For embryonic stem cells created from embryos created after April 26, 2005, the embryonic stem cells must be derived from embryos and under conditions in compliance with the Guidelines for Human Embryonic Stem Cell Research established by the National Research Council Institute of Medicine of the National Academies (the NAS Guidelines).
(iii) For embryonic stem cells created after April 26, 2005 from embryos generated prior to April 26, 2005, and which do not meet the NAS Guidelines, the embryonic stem cells must meet one of the conditions set forth in paragraph (i) above and be created using protocols substantially in compliance with the requirements of the NAS Guidelines.
IPSCIO Record ID: 802
Cells shall mean in vitro generated, growth factor responsive neural stem cells to the extent claimed in the Patent Rights and shall include all progeny and derivatives of such stem cells (including Progenitor Cells and their progeny and Stem Cells and their progeny) and Cell shall mean one of such cells. An in vitro generated growth factor responsive neural stem cell shall include a neural stem cell, or its derivatives or progeny, which exhibits one or more of the following characteristics
(a) is dependent on the presence of a growth factor for survival and viability, or (b) proliferates or differentiates due to the presence of a growth factor, whether alone or in combination with another biologically active molecule; and
An EGF-responsive neuronal stem cell includes
a neuronal stem cell, or its derivatives or progeny, which exhibits one or more of the following characteristics
(a) is dependent on the presence of EGF for survival and viability, or (b) proliferates or differentiates due to the presence of EGF, whether alone or in combination with another biologically active molecule all to the extent claimed or allowed under the Patent Rights.
Product shall mean any product utilizing the Cells and the manufacture, use, or sale of which, but for the license granted to the Company hereunder, would infringe any claim of the Patent
Services shall mean any use of the Cells or the Cell Technology to perform a service for a third party for compensation, where such use would, but for the license granted to the Company hereunder, infringe any claim of the Patent Rights.
(a) for Cell Replacement Therapy; (b) for the purposes of Transplantation anywhere in the human body for the treatment or prevention of human disease, injury, or disorder; (c) for augmenting the function of endogenous cells by Transplantation or Cell Replacement Therapy; and (d) for the purposes of transplantation therapy in general (e.g., Transplantation of the Cells for delivery of one or more Agents).
IPSCIO Record ID: 204653
IPSCIO Record ID: 7409
UC Case Number
U.S. Application Number or U.S. Patent Number
Intellectual Property includes the method for detecting the differentiation of multipotential human embryonic stem cells to glial-restricted progenitor cells that generate pure populations of oligodendrocytes for remyelination and treatment of spinal cord injury.
IPSCIO Record ID: 27800
One area of use is to increase the number of stem cells available to convert into pancreatic islet cells, thereby increasing the number of islet cells that can be impl. Producing new islet cells has proven to be a difficult task. Differentiating pluripotent stem cells into islet cells has been accomplished in the laboratory and is still hoped to be the answer for treating or possibly curing type 1 diabetes.
This treatment for type 1 diabetes would be to transplant insulin-producing islet cells into the body. The Edmonton Protocol is a method of implanting pancreatic islets into the liver for the treatment of type 1 diabetes.
IPSCIO Record ID: 273421
With this amendment, The University Regents grant a world-wide license under The Universitys undivided interest in Patent Rights to make, have made, use, sell, offer to sell and import Product and to practice Licensed Method in the Field.
The patents include Isolation of Stromal Cells from Adipose Tissue, Isolation of Mesenchymal Stem Cells from Adipose Tissue, and, Adipose-Derived Stem Cells and Lattices.
Product means Research Product and Clinical Product.
Licensee is commercializing an automated device called Celution, which when operated in conjunction with various disposable component parts is capable of producing a heterogeneous isolate of the material naturally occurring in adipose tissue including unmodified amounts of stem cells and other regenerative cells, intended for human therapeutic, diagnostic, cosmetic and other uses.
The patented CelutionÂ® family of products process patientsâ€™ adipose-derived stem and regenerative cells (ADRCs) at the point of care. The CelutionÂ® family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. Licensee commercialization model is based on the sale of CelutionÂ® Systems and on generating recurring revenues from the single-use consumable sets.
Commercial activities are currently focused on cosmetic and reconstructive surgery in Europe and Asia-Pacific, where Cytoriâ€™s core product, the CelutionÂ® System, provides physicians with clinical grade stem and regenerative cells.
IPSCIO Record ID: 4396
Genes for Human Telomerase Reverse Transcriptase and Telomerase Variants
Nucleic Acids Encoding Human Telomerase Reverse Transcriptase and Related Homologs
Nucleic Acid Compositions for Eliciting an Immune Response Against Telomerase Reverse Transcriptase
Human Telomerase Reverse Transcriptase Polypeptides
Field of Use means use of telomerase as an antigen in an immunotherapeutic product for use in humans wherein the telomerase antigen is delivered using (i) patient monocyte-derived dendritic cells, or other patient blood or bone marrow-derived antigen presenting cells, (ii) human embryonic stem cell derived dendritic cells or other antigen presenting cells, or (iii) induced pluripotent stem cell derived dendritic cells or other antigen presenting cells.